News

Mauna Kea Technologies Announces 2022 Nine Month Sales Results

27 October 2022

Global 9-month sales slightly down (5%) at €4.8 million while sales in the United States grew 23%

Mauna Kea Technologies today announced its sales results for the first nine months of 2022.

Sacha Loiseau, Ph.D., Chairman and Chief Executive Officer of Mauna Kea Technologies, commented: "Despite a challenging operating environment and the reallocation of resources associated with the strategic reorganization announced in late 2021, our commercial team has remained engaged and delivered satisfactory results, including 23% YTD growth in the United States.” Mr. Loiseau continued, “As I return to my executive leadership role, I am focused on improving the company's overall efficiency, capturing near-term growth opportunities and accelerating our development activities with strategic partners.”

​​​​For additional details and financial results, please see the full press release.

Latest News

Mauna Kea Technologies Announces 2026 Half-Year Results 

Mauna Kea Technologies Announces 2026 Half-Year Results 

Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer 

Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer 

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts 

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts 

No results found.